Sangamo Therapeutics (SGMO) Return on Sales (2016 - 2025)
Historic Return on Sales for Sangamo Therapeutics (SGMO) over the last 17 years, with Q3 2025 value amounting to 60.12%.
- Sangamo Therapeutics' Return on Sales fell 603400.0% to 60.12% in Q3 2025 from the same period last year, while for Sep 2025 it was 3.42%, marking a year-over-year decrease of 8400.0%. This contributed to the annual value of 1.69% for FY2024, which is 2300.0% down from last year.
- Per Sangamo Therapeutics' latest filing, its Return on Sales stood at 60.12% for Q3 2025, which was down 603400.0% from 1.09% recorded in Q2 2025.
- Sangamo Therapeutics' 5-year Return on Sales high stood at 0.22% for Q3 2024, and its period low was 102.06% during Q1 2024.
- Moreover, its 5-year median value for Return on Sales was 2.01% (2022), whereas its average is 18.12%.
- Per our database at Business Quant, Sangamo Therapeutics' Return on Sales plummeted by -1021900bps in 2024 and then soared by 1003900bps in 2025.
- Sangamo Therapeutics' Return on Sales (Quarter) stood at 2.16% in 2021, then increased by 11bps to 1.91% in 2022, then crashed by -1448bps to 29.53% in 2023, then surged by 88bps to 3.6% in 2024, then crashed by -1570bps to 60.12% in 2025.
- Its last three reported values are 60.12% in Q3 2025, 1.09% for Q2 2025, and 4.75% during Q1 2025.